Merck Enlists Isomorphic Labs for Undisclosed Oncology Target
Merck has identified a strategically important oncology target and amassed significant wet-lab data through its internal research. Now, the pharmaceutical giant is turning to Isomorphic Labs, the DeepMind spinoff, to determine whether its artificial intelligence models can leverage that data to identify promising small-molecule candidates more rapidly.
Also Read
- Pediatric Imaging Associated with Dose-Dependent Brain Tumor Risk in Children and Adolescents
- Trump Administration Accused of Rolling Back Cancer Protections, Report Finds
- GLP-1 Spending and the Care Management Measurement Gap
- VA Study Links Updated COVID Vaccine to Lower Hospitalization Rates Among Nearly 1 Million Veterans


